Immutep says it is less than three years away from a potential “blockbuster drug” after raising $100 million to finalise late-stage trials of its lung cancer treatment.

Shares in the ASX-listed oncology therapy hopeful have risen some 45 per cent in the past 12 months as the company nears the commercialisation of its drug, Efti. The therapy is combined with another top-selling cancer treatment, Merck’s Keytruda, and coupled with chemotherapy to extend the life of patients.